Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: May 28, 2003
Last updated: August 4, 2008
Last verified: August 2008

The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

Condition Intervention Phase
Ocular Hypertension
Drug: Travoprost
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Study Start Date: April 2003
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Subjects 18 years of age or older
  • of either sex
  • of any race
  • diagnosed with ocular hypertension or open angle glaucoma
  Contacts and Locations
Please refer to this study by its identifier: NCT00061503

United States, Nebraska
Alcon Call Center
Call for Details, Nebraska, United States
Sponsors and Collaborators
Alcon Research
  More Information

No publications provided Identifier: NCT00061503     History of Changes
Other Study ID Numbers: C-01-55
Study First Received: May 28, 2003
Last Updated: August 4, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
Ocular Hypertension

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 17, 2014